Shareholder Returns

Novo’s shareholder return since 2019 exceeds DKK 300 bn, with a proposed final dividend of DKK 11.70 for 2025. The company’s gross margin fell to 81 % from 84.7 % in 2024 due to amortisation and restructuring costs, and operating profit fell 1 % in DKK. Overall, the company treats nearly 46 m patients worldwide and aims to preserve its leadership in obesity and diabetes care while navigating pricing pressures, patent expiries, and new market entrants.